Mark Herrmann – författare

Pharmaceutical and medical device manufacturers face relentless and costly waves of product liability claims across U.S. federal and state courts, spanning individual suits, consolidated multidistrict litigation and coordinated proceedings, multi-plaintiff actions, and class actions. As this complex area of litigation continues to expand-often into more treacherous and plaintiff-friendly venues-the stakes for getting strategy right, early and often, have never been higher.The third edition of Drug and Device Product Liability Litigation Strategy equips litigators with clear, practical guidance from pre-litigation investigations through trial. Reflecting significant developments since the prior edition, it distills the current and evolving legal landscape impacting drug and device lawyers, and offers actionable analysis on the issues that are most likely to influence outcomes: pre-litigation investigation and risk assessment, document preservation and fact discovery, coordination in MDLs and state proceedings, class action challenges, developments in preemption and personal jurisdiction case law, admissibility of expert testimony, dispositive and pre-trial motion practice, jury selection, and trial strategy. This edition highlights strategic inflection points and delivers practice-oriented insights to streamline case management and sharpen advocacy. With its emphasis on strategy and results, it is an indispensable resource for lawyers navigating high-profile drug and device litigation in a continually shifting environment.

Thousands of lawsuits continue to be filed in federal and state courts each year to seek recovery from manufacturers of pharmaceuticals and medical devices. These lawsuits include individual actions, actions consolidated into federal multidistrict litigation, multi-plaintiff cases, and class actions. As drug and device litigation remains as active as ever, companies that develop new drugs and devices continue to face significant and often costly product liability litigation in the United States.This new and revised edition of Drug & Device Product Liability Litigation Strategy provides detailed background, discussion, and strategic guidance to those practicing in this field. The book offers lawyers a detailed analysis of the full range of issues involved in drug and device litigation, including pre-litigation counselling, document preservation and discovery, consolidation and mass joinder, multidistrict litigation, class action litigation, admissibility of expert testimony, dispositive and pre-trial motion practice, jury selection, and trial. This second edition not only contains thorough revisions to reflect recent changes in the legal landscape following key court decisions and statutory developments in areas such as preemption, admissibility of expert testimony, the learned intermediary doctrine, and innovator liability, but also contains new analyses of issues such as personal jurisdiction, pre-litigation counselling, and the amended Federal Rules of Civil Procedure. It is an indispensable guide to lawyers handling cases in this high-stake, high-profile, and rapidly evolving area.